Annals of Oncology最新文献

{"title":"105P HER2 amplification drives resistance to anti-EGFR therapy in RAS/BRAF wild-type metastatic colorectal cancer: A real-world study","authors":"U. Ozkerim, O. Kinikoglu","doi":"10.1016/j.annonc.2026.05.106","DOIUrl":"10.1016/j.annonc.2026.05.106","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S41"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"90P Association between serum VEGF-A and treatment response in metastatic colorectal cancer treated with FOLFIRI plus aflibercept: An exploratory analysis of the HGCSG1801","authors":"K. Harada, H. Nakatsumi, K. Sawada, A. Ishiguro, T. Nakamura, S. Sogabe, T. Ando, Y. Sasaki, A. Yoshikawa, M. Nakamura, M. Dazai, M. Tateyama, O. Muto, M. Kotaka, T. Sagawa, T. Muranaka, K. Hatanaka, R. Takagi, Y. Sakata, Y. Komatsu","doi":"10.1016/j.annonc.2026.05.091","DOIUrl":"10.1016/j.annonc.2026.05.091","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S34"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"21P Outcomes of metastasectomy in metastatic colorectal cancer: A real-world retrospective cohort from a Low-Middle-Income Country","authors":"O.H. El Khatib, A.M. Alghrabli, M. Harb, H. Jaber, A.F. Abdelqader, A. Albanna, M. Akileh, A.A. Yaseen, R. Turfa, T.A. Awabdeh","doi":"10.1016/j.annonc.2026.05.024","DOIUrl":"10.1016/j.annonc.2026.05.024","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S11"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"71P Early- versus late-onset RAS wild-type (RASWT) metastatic colorectal cancer (mCRC) patients receiving first-line (1L) anti-EGFR therapy: A pooled ctDNA analysis of three clinical trials","authors":"V. Martelli, J. Vidal Barrull, P. Ciracì, P. Berenguer-Molins, A. Sibilio, C. Fernandez Rodriguez, B. Bellosillo Paricio, J.L. Linares, V. Conca, C. Ugolini, P. Vignali, M.B. Landi, G. Martini, S. Napolitano, F. De Vita, R. Bordonaro, F. Ciardiello, D. Ciardiello, C. Cremolini, C. Montagut","doi":"10.1016/j.annonc.2026.05.072","DOIUrl":"10.1016/j.annonc.2026.05.072","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S26-S27"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6RO Calderasib (MK-1084) for KRAS G12C-mutated (mut) advanced colorectal cancer (CRC): Results from KANDLELIT-001","authors":"R. Dziadziuszko, V. Moreno Garcia, I. Lugowska, C.I. Rojas, I.M. Garcia, O. Dizdar, J. Xue, M. Gottfried, Y. Rottenberg, M. Simonelli, M. Kwiatkowski, M.A.N. Sendur, G. Ursol, O. Kobziev, C-C. Lin, T. Jemielita, M. Ayers, S.Y. Choi, M. Garrido","doi":"10.1016/j.annonc.2026.05.010","DOIUrl":"10.1016/j.annonc.2026.05.010","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S6"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148532017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"44P Dual PI3Kδ/γ inhibition potentiates radiotherapy by reprogramming tumor-associated macrophages via the cGAS–STING–IFN-I axis in colorectal cancer","authors":"Y.H. Kim, J-S. Kim","doi":"10.1016/j.annonc.2026.05.046","DOIUrl":"10.1016/j.annonc.2026.05.046","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S17"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148532092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"87P Low-dose nivolumab as first-line therapy in MSI-H metastatic colorectal cancer: Results from a prospective single-arm phase II study","authors":"K.B. Luniya, V.S. Ostwal, M. Kazi, A. Ramaswamy, P.G. Bhargava, A. Mehta, G. John, A. Saklani, A. De Souza, O. Shetty, A. Baheti, P. Anand, D. Naughane, G. Deshpande, S. Yadav, R.K. Kaushal, S.K. Ankathi, T.K. Garkal","doi":"10.1016/j.annonc.2026.05.088","DOIUrl":"10.1016/j.annonc.2026.05.088","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S32-S33"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148539793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma","authors":"J.C. Hassel ,&nbsp;A. Arance ,&nbsp;M.S. Carlino ,&nbsp;L. Mortier ,&nbsp;P.A. Ascierto ,&nbsp;P. Rutkowski ,&nbsp;S. Sandhu ,&nbsp;C. Coetzee ,&nbsp;I. Puzanov ,&nbsp;S.B. Karaca ,&nbsp;A.M. Eggermont ,&nbsp;O. Hamid ,&nbsp;S. Grabbe ,&nbsp;A. Poklepovic ,&nbsp;T. Amaral ,&nbsp;D. Schadendorf ,&nbsp;B. Schilling ,&nbsp;A. Vedel Christiansen ,&nbsp;B. Wang ,&nbsp;A. Wakatsuki Pedersen ,&nbsp;I.M. Svane","doi":"10.1016/j.annonc.2026.04.010","DOIUrl":"10.1016/j.annonc.2026.04.010","url":null,"abstract":"<div><h3>Background</h3><div>IO102-IO103, an investigational, immune-modulatory cancer vaccine, targets both tumor cells and immune-suppressive cells within the tumor microenvironment through activation and expansion of T cells against indoleamine 2,3-dioxygenase 1–positive and/or programmed death ligand 1 (PD-L1)-positive cells.</div></div><div><h3>Patients and methods</h3><div>This open-label, phase III trial randomly assigned 407 patients with untreated advanced melanoma in a 1:1 ratio to receive subcutaneous IO102-IO103 (85 μg each) plus pembrolizumab 200 mg intravenously every 3 weeks or pembrolizumab alone for up to 2 years. The primary endpoint was progression-free survival (PFS) by blinded independent central review per RECIST v1.1.</div></div><div><h3>Results</h3><div>The median PFS was 19.4 months [95% confidence interval (CI) 9.7 to not reached] for IO102-IO103 plus pembrolizumab versus 11.0 months (95% CI 6.0-14.8) for pembrolizumab [hazard ratio (HR) (95% CI) 0.77 (0.58-1.00), <em>P</em> = 0.0558]; the statistical significance threshold (<em>P</em> ≤ 0.045) was missed. A longer PFS was observed in the combination arm across most subgroups, notably in patients with PD-L1-negative tumors [median PFS 16.6 versus 3.0 months (HR 0.54, 95% CI 0.35-0.85)], anti-PD-1 naïve patients [24.8 versus 11.0 months (HR 0.74, 95% CI 0.56-0.98)], proto-oncogene <em>B-Raf</em> (BRAF)-mutated tumors, or elevated lactate dehydrogenase. There was no increase in the frequency of treatment-related adverse events grade ≥3 (14.5% versus 15.6%) or of serious adverse events (32.0% versus 32.3%) in the vaccine arm. Local vaccine-related injection site reactions were reported in 56.0% of patients and were mostly grade 1/2.</div></div><div><h3>Conclusions</h3><div>IO102-IO103 plus pembrolizumab prolonged PFS compared with pembrolizumab alone in patients with advanced melanoma in the first-line setting; however, statistical significance was missed for the primary endpoint. The combination was well tolerated with no added significant systemic toxicity. These data show the potential benefit of this combination in untreated advanced melanoma.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 999-1010"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology","authors":"M. Svrcek ,&nbsp;L. Verlingue","doi":"10.1016/j.annonc.2026.02.019","DOIUrl":"10.1016/j.annonc.2026.02.019","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 886-888"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"63P Biologic sequencing of bevacizumab and anti-EGFR therapy in MSS RAS/BRAF wild-type right-sided metastatic colorectal cancer","authors":"O. Kutlu,&nbsp;G. Gül,&nbsp;S. Goktas Aydin,&nbsp;R. Gonul,&nbsp;A. Terzi,&nbsp;M.N. Baser,&nbsp;B.N. Tazebay,&nbsp;H. Odabasi,&nbsp;M. Mildanoglu,&nbsp;E. Cicek,&nbsp;M. Kurul Yeniay,&nbsp;R. Arikan Erdogan,&nbsp;S. Tas,&nbsp;E. Sertesen,&nbsp;E.S. Hafizoglu,&nbsp;D. Gunenc,&nbsp;H. Taskaynatan,&nbsp;O. Ozdemir,&nbsp;B. Karabulut","doi":"10.1016/j.annonc.2026.05.065","DOIUrl":"10.1016/j.annonc.2026.05.065","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S24-S25"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148523438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}